AllergoOncology

The role of IgE-mediated allergy in cancer

E. Jensen-Jarolim, G. Achatz, M. C. Turner, S. Karagiannis, F. Legrand, M. Capron, M. L. Penichet, J. A. Rodríguez, A. G. Siccardi, L. Vangelista, A. B. Riemer, H. Gould

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Epidemiological studies have suggested inverse associations between allergic diseases and malignancies. As a proof of concept for the capability of immunoglobulin E (IgE) to destruct tumor cells, several experimental strategies have evolved to specifically target this antibody class towards relevant tumor antigens. It could be demonstrated that IgE antibodies specific to overexpressed tumor antigens have been superior to any other immunoglobulin class with respect to antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) reactions. In an alternative approach, IgE nonspecifically attached to tumor cells proved to be a powerful adjuvant establishing tumor-specific immune memory. Active Th2 immunity could also be achieved by applying an oral immunization regimen using mimotopes, i.e. epitope mimics of tumor antigens. The induced IgE antibodies could be cross-linked by live tumor cells leading to tumoricidic mediator release. Thus, IgE antibodies may not only act in natural tumor surveillance, but could possibly also be exploited for tumor control in active and passive immunotherapy settings. Thereby, eosinophils, mast cells and macrophages can be armed with the cytophilic IgE and become potent anti-tumor effectors, able to trace viable tumor cells in the tissues. It is strongly suggested that the evolving new field AllergoOncology will give new insights into the role of IgE-mediated allergy in malignancies, possibly opening new avenues for tumor therapy.

Original languageEnglish
Pages (from-to)1255-1266
Number of pages12
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume63
Issue number10
DOIs
Publication statusPublished - Oct 2008
Externally publishedYes

Fingerprint

Immunoglobulin E
Hypersensitivity
Neoplasms
Neoplasm Antigens
Antibodies
Immunoglobulin Isotypes
Active Immunity
Active Immunotherapy
Passive Immunization
Phagocytosis
Eosinophils
Mast Cells
Epidemiologic Studies
Epitopes
Immunization
Macrophages

Keywords

  • AllergoOncology
  • Cancer
  • Eosinophils
  • IgE
  • Tumoricidic

ASJC Scopus subject areas

  • Immunology

Cite this

Jensen-Jarolim, E., Achatz, G., Turner, M. C., Karagiannis, S., Legrand, F., Capron, M., ... Gould, H. (2008). AllergoOncology: The role of IgE-mediated allergy in cancer. Allergy: European Journal of Allergy and Clinical Immunology, 63(10), 1255-1266. https://doi.org/10.1111/j.1398-9995.2008.01768.x

AllergoOncology : The role of IgE-mediated allergy in cancer. / Jensen-Jarolim, E.; Achatz, G.; Turner, M. C.; Karagiannis, S.; Legrand, F.; Capron, M.; Penichet, M. L.; Rodríguez, J. A.; Siccardi, A. G.; Vangelista, L.; Riemer, A. B.; Gould, H.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 63, No. 10, 10.2008, p. 1255-1266.

Research output: Contribution to journalArticle

Jensen-Jarolim, E, Achatz, G, Turner, MC, Karagiannis, S, Legrand, F, Capron, M, Penichet, ML, Rodríguez, JA, Siccardi, AG, Vangelista, L, Riemer, AB & Gould, H 2008, 'AllergoOncology: The role of IgE-mediated allergy in cancer', Allergy: European Journal of Allergy and Clinical Immunology, vol. 63, no. 10, pp. 1255-1266. https://doi.org/10.1111/j.1398-9995.2008.01768.x
Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M et al. AllergoOncology: The role of IgE-mediated allergy in cancer. Allergy: European Journal of Allergy and Clinical Immunology. 2008 Oct;63(10):1255-1266. https://doi.org/10.1111/j.1398-9995.2008.01768.x
Jensen-Jarolim, E. ; Achatz, G. ; Turner, M. C. ; Karagiannis, S. ; Legrand, F. ; Capron, M. ; Penichet, M. L. ; Rodríguez, J. A. ; Siccardi, A. G. ; Vangelista, L. ; Riemer, A. B. ; Gould, H. / AllergoOncology : The role of IgE-mediated allergy in cancer. In: Allergy: European Journal of Allergy and Clinical Immunology. 2008 ; Vol. 63, No. 10. pp. 1255-1266.
@article{22178fa3f4b7462890b55f11de0d01ce,
title = "AllergoOncology: The role of IgE-mediated allergy in cancer",
abstract = "Epidemiological studies have suggested inverse associations between allergic diseases and malignancies. As a proof of concept for the capability of immunoglobulin E (IgE) to destruct tumor cells, several experimental strategies have evolved to specifically target this antibody class towards relevant tumor antigens. It could be demonstrated that IgE antibodies specific to overexpressed tumor antigens have been superior to any other immunoglobulin class with respect to antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) reactions. In an alternative approach, IgE nonspecifically attached to tumor cells proved to be a powerful adjuvant establishing tumor-specific immune memory. Active Th2 immunity could also be achieved by applying an oral immunization regimen using mimotopes, i.e. epitope mimics of tumor antigens. The induced IgE antibodies could be cross-linked by live tumor cells leading to tumoricidic mediator release. Thus, IgE antibodies may not only act in natural tumor surveillance, but could possibly also be exploited for tumor control in active and passive immunotherapy settings. Thereby, eosinophils, mast cells and macrophages can be armed with the cytophilic IgE and become potent anti-tumor effectors, able to trace viable tumor cells in the tissues. It is strongly suggested that the evolving new field AllergoOncology will give new insights into the role of IgE-mediated allergy in malignancies, possibly opening new avenues for tumor therapy.",
keywords = "AllergoOncology, Cancer, Eosinophils, IgE, Tumoricidic",
author = "E. Jensen-Jarolim and G. Achatz and Turner, {M. C.} and S. Karagiannis and F. Legrand and M. Capron and Penichet, {M. L.} and Rodr{\'i}guez, {J. A.} and Siccardi, {A. G.} and L. Vangelista and Riemer, {A. B.} and H. Gould",
year = "2008",
month = "10",
doi = "10.1111/j.1398-9995.2008.01768.x",
language = "English",
volume = "63",
pages = "1255--1266",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley Blackwell",
number = "10",

}

TY - JOUR

T1 - AllergoOncology

T2 - The role of IgE-mediated allergy in cancer

AU - Jensen-Jarolim, E.

AU - Achatz, G.

AU - Turner, M. C.

AU - Karagiannis, S.

AU - Legrand, F.

AU - Capron, M.

AU - Penichet, M. L.

AU - Rodríguez, J. A.

AU - Siccardi, A. G.

AU - Vangelista, L.

AU - Riemer, A. B.

AU - Gould, H.

PY - 2008/10

Y1 - 2008/10

N2 - Epidemiological studies have suggested inverse associations between allergic diseases and malignancies. As a proof of concept for the capability of immunoglobulin E (IgE) to destruct tumor cells, several experimental strategies have evolved to specifically target this antibody class towards relevant tumor antigens. It could be demonstrated that IgE antibodies specific to overexpressed tumor antigens have been superior to any other immunoglobulin class with respect to antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) reactions. In an alternative approach, IgE nonspecifically attached to tumor cells proved to be a powerful adjuvant establishing tumor-specific immune memory. Active Th2 immunity could also be achieved by applying an oral immunization regimen using mimotopes, i.e. epitope mimics of tumor antigens. The induced IgE antibodies could be cross-linked by live tumor cells leading to tumoricidic mediator release. Thus, IgE antibodies may not only act in natural tumor surveillance, but could possibly also be exploited for tumor control in active and passive immunotherapy settings. Thereby, eosinophils, mast cells and macrophages can be armed with the cytophilic IgE and become potent anti-tumor effectors, able to trace viable tumor cells in the tissues. It is strongly suggested that the evolving new field AllergoOncology will give new insights into the role of IgE-mediated allergy in malignancies, possibly opening new avenues for tumor therapy.

AB - Epidemiological studies have suggested inverse associations between allergic diseases and malignancies. As a proof of concept for the capability of immunoglobulin E (IgE) to destruct tumor cells, several experimental strategies have evolved to specifically target this antibody class towards relevant tumor antigens. It could be demonstrated that IgE antibodies specific to overexpressed tumor antigens have been superior to any other immunoglobulin class with respect to antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) reactions. In an alternative approach, IgE nonspecifically attached to tumor cells proved to be a powerful adjuvant establishing tumor-specific immune memory. Active Th2 immunity could also be achieved by applying an oral immunization regimen using mimotopes, i.e. epitope mimics of tumor antigens. The induced IgE antibodies could be cross-linked by live tumor cells leading to tumoricidic mediator release. Thus, IgE antibodies may not only act in natural tumor surveillance, but could possibly also be exploited for tumor control in active and passive immunotherapy settings. Thereby, eosinophils, mast cells and macrophages can be armed with the cytophilic IgE and become potent anti-tumor effectors, able to trace viable tumor cells in the tissues. It is strongly suggested that the evolving new field AllergoOncology will give new insights into the role of IgE-mediated allergy in malignancies, possibly opening new avenues for tumor therapy.

KW - AllergoOncology

KW - Cancer

KW - Eosinophils

KW - IgE

KW - Tumoricidic

UR - http://www.scopus.com/inward/record.url?scp=51349168516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51349168516&partnerID=8YFLogxK

U2 - 10.1111/j.1398-9995.2008.01768.x

DO - 10.1111/j.1398-9995.2008.01768.x

M3 - Article

VL - 63

SP - 1255

EP - 1266

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 10

ER -